ReviewDrug discovery today2008
Ophthalmic light sensitive nanocarrier systems.
Review in Drug discovery today, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 71 citations in OpenAlex.
- Light Sensitive Liposomes: A Novel Strategy for Targeted Drug Delivery.Pharmaceutical nanotechnology · 2025Review
- Age-Related Macular Degeneration (AMD): Pathophysiology, Drug Targeting Approaches, and Recent Developments in Nanotherapeutics.Medicina (Kaunas, Lithuania) · 2024Review
- Light-responsive biomaterials for ocular drug delivery.Drug delivery and translational research · 2023Review
- Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD).International journal of molecular sciences · 2021Review
- Peptidomimetics Therapeutics for Retinal Disease.Biomolecules · 2021Review
- ISOPTJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2019Article
- Light-Triggered Cellular Delivery of Oligonucleotides.Pharmaceutics · 2019Article
- Mechanoresponsive materials for drug delivery: Harnessing forces for controlled release.Advanced drug delivery reviews · 2017Review
- Nanocrystal for ocular drug delivery: hope or hype.Drug delivery and translational research · 2016Review
- Intraocular Implants for the Treatment of Autoimmune Uveitis.Journal of functional biomaterials · 2015Review
- Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.Progress in retinal and eye research · 2013Review
- Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab.Molecular pharmaceutics · 2013Article
- Targeted cytosolic delivery of cell-impermeable compounds by nanoparticle-mediated, light-triggered endosome disruption.Nano letters · 2010Article
- Inner blood-retinal barrier transporters: role of retinal drug delivery.Pharmaceutical research · 2009Review
- Shining light on nanotechnology to help repair and regeneration.Biotechnology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The eye is afflicted by chronic vision debilitating neovascular disorders, such as age-related macular degeneration, proliferative diabetic retinopathy, and corneal angiogenesis. Photodynamic therapy (PDT) is an innovative, evolving approach for treating neovascular diseases of the eye. PDT refers to the process of activating a light sensitive agent or carrier with non-thermal light to induce chemical reactions that ameliorate a pathological condition. Key components of PDT include a photosensitizer, a colloidal carrier or formulation and a light source. This article summarizes currently available clinical PDTs, desirable features of PDTs and photosensitizers, useful light sources for PDT and investigational nanosystems, and colloidal carriers for PDT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.